Resmed – Algo Buy
ResMed is under Algo Engine buy conditions and we see buying support building.
ResMed will release 2Q21 earnings on Thursday 28 January

ResMed is under Algo Engine buy conditions and we see buying support building.
ResMed will release 2Q21 earnings on Thursday 28 January
ResMed is under Algo Engine buy conditions and we see buying support building.
ResMed is under Algo Engine buy conditions and is a current holding in our ASX model portfolio.
Resmed reported better than expected 1Q21 earnings with group revenue up 10% and NPAT up 37% on the same time last year.
At 35x PE Resmed remains expensive and will need to maintain double-digit earnings growth to sustain the current valuation.
Buy on future share price weakness.
ResMed is under Algo Engine buy conditions and is a current holding in our ASX top 100 model portfolio.
RMD announced 4Q20 earnings, which were better-than-expected, underpinned by robust COVID-19 ventilator demand. However, modest revenue growth is expected in the near-term, implying limited near-term growth.
The 40x PE multiple looks too rich for the current earnings outlook. The forward dividend yield is 1%.
We suggest waiting for the next Algo buy signal to re-enter RMD on a pullback. Our new entry target is $22.
ResMed short term traders may wish to take profit on RMD, following the 6% rally.
ResMed is under Algo Engine buy conditions and we see buying support building.
Accumulate RMD within the $22 – $23 price range.
ResMed is a current holding in our ASX 100 model portfolio.
The company reports 1Q20 earnings on 25 October and we expect revenue growth to be 15%+ and EBIT to be up 10%+ on the same time last year.
We look for an entry-level into RMD on the current price weakness and will update our readers further, following the earnings result.
ResMed is under Algo Engine buy conditions and is a current holding in our ASX 100 model portfolio.
RMD report earnings on the 24th Oct and the market is looking for 10%+ in EPS growth. We expect buying support to increase ahead of the result and see support building at $19.50.
ResMed is under Algo Engine buy conditions and is a current holding in our ASX 100 model portfolio.
Buying interest is again building near the $14.00 price range.
We recommend adding Resmed to your watch list.
RMDis a global company involved in the development and manufacturing of medical products for the treatment of respiratory disorders. Global mask sales increased 10%+ on the same time last year.
Low returns from new acquisitions, disappointed investors and the soft 2Q19 earnings update resulted in the stock falling by over 10%
It’s difficult to say with certainly where buyers will step back in, but we are confident of the long-term story with Resmed.
The chart below illustrates the lower band where we see deep value for investors willing to take a 1 – 3 year outlook.